financetom
Business
financetom
/
Business
/
Rare earths miner Lynas Q4 revenue falls on output slump, lower prices
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Rare earths miner Lynas Q4 revenue falls on output slump, lower prices
Jul 22, 2024 6:18 PM

By Rajasik Mukherjee

(Reuters) -Lynas Rare Earths posted a drop in quarterly revenue on Tuesday, hit by production decline at its Kalgoorlie facility in Western Australia and lower underlying prices, sending its shares to a more than three-month low.

Shares of the rare earths miner fell as much as 2.8% to hit A$5.880, their lowest level since April 11.

Lynas' Malaysian operations also went through a maintenance shutdown during the reported period, which the rare earths miner indicated took over a month.

Total rare-earth oxide output for the fourth quarter ended June 30 was at 2,188 REO tons, plunging more than 50% from a year ago.

"The main bearings on one of the kilns failed and required a maintenance shutdown that took over a month," Lynas said, referring to its downstream Malaysian operations.

Sluggish demand from green energy companies and electric automakers, coupled with rising global supply, have severely dented rare earth products' prices.

"Rare-earths markets continue to be impacted by weakened Chinese demand and high-supply chain inventories....don't currently see near-term support on price," Jefferies analysts wrote in a note.

Lynas said market prices remained low despite a slight improvement in Chinese domestic end-product demand.

The average selling price was A$42.3 per kilogram in the quarter, the company said, compared with A$43.5 per kg a year earlier.

Earlier this month, Lynas flagged disruptions to BHP's ability to supply sulphuric acid, a key ingredient in rare-earths processing, to its Kalgoorlie facility, after BHP suspended its Western Australia nickel operations.

Lynas said it had been working on contingencies with the world's largest miner aimed at the continued supply of acid to the Kalgoorlie plant.

The world's largest producer of rare earths outside China posted sales revenue of A$136.6 million ($90.72 million) for the quarter, compared with A$157.5 million a year ago.

($1 = 1.5058 Australian dollars)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Auxly Cannabis Swings to Q4 Profit On Higher Revenue
Auxly Cannabis Swings to Q4 Profit On Higher Revenue
Mar 20, 2025
08:53 AM EDT, 03/20/2025 (MT Newswires) -- Auxly Cannabis Group ( CBWTF ) , a consumer-packaged goods company in the cannabis products market, on Thursday reported a swing to profit in the fourth quarter as well as a rise in revenue. The company reported net income for the three months ended Dec. 31, of $4.4 million compared with net loss...
Sector Update: Consumer
Sector Update: Consumer
Mar 20, 2025
08:53 AM EDT, 03/20/2025 (MT Newswires) -- Consumer stocks were flat to higher pre-bell Thursday as the Consumer Staples Select Sector SPDR Fund (XLP) was flat and the Consumer Discretionary Select Sector SPDR Fund (XLY) was up 0.5% recently. PDD Holdings ( PDD ) shares declined by more than 3% after the company reported Q4 revenue that missed analysts' expectations....
Amazon, Flipkart found to have violated Indian quality control rules during warehouse raids
Amazon, Flipkart found to have violated Indian quality control rules during warehouse raids
Mar 20, 2025
March 20 (Reuters) - Retail giants Amazon ( AMZN ) and Walmart ( WMT )-owned Flipkart violated Indian quality control rules by stocking products that did not have the required standards certificate, India's top government-run product certification agency said on Thursday. Raids on warehouses operated by both firms, conducted on Wednesday by the Burueau of Indian Standards in the Tiruvallur...
Esperion Therapeutics Says FDA Clears Phase 3 Bempedoic Acid Trial in Hypercholesterolemia
Esperion Therapeutics Says FDA Clears Phase 3 Bempedoic Acid Trial in Hypercholesterolemia
Mar 20, 2025
08:52 AM EDT, 03/20/2025 (MT Newswires) -- Esperion Therapeutics ( ESPR ) said Thursday the US Food and Drug Administration has confirmed that it has enough data to proceed with phase 3 studies of bempedoic acid as a monotherapy and in combination with ezetimibe in children with heterozygous and homozygous familial hypercholesterolemia. The company said it plans to begin phase...
Copyright 2023-2026 - www.financetom.com All Rights Reserved